Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?

On June 24, Nektar Therapeutics NASDAQ: NKTR stock exploded nearly 157% following news that Rezpeg, the company’s experimental treatment for atopic dermatitis (eczema), successfully met its primary and secondary goals in a Phase 2b trial. Nektar joined a wave of micro-cap biotechnology stocks surging after promising clinical trial results. And two Wall Street analysts believe shares could go even higher.Get Nektar Therapeutics alerts:BTIG Research and HC Wainwright updated their price targets on the stock t ...